<DOC>
	<DOCNO>NCT02280096</DOCNO>
	<brief_summary>Twenty four RRMS patient age 18 , similar degree disability , evolution last 6 month , first-line immunomodulatory therapy stable disease ( one outbreak per year ) include present study . Patients administer neuropsychological test battery select study divide two session one half-hour . Emotional state assess Beck Depression Inventory different session . Cognitive impairment define alteration two neuropsychological test . Patients divide randomly two group one receive placebo one 4-AP period four month increase dos .</brief_summary>
	<brief_title>Efficacy Safety 4-aminopyridine Cognitive Performance Motor Function Patients With Multiple Sclerosis</brief_title>
	<detailed_description>Consecutive patient stable multiple sclerosis recruit neurological service IMSS hospital CMN Siglo XXI period 1 year . Of meet inclusion criterion , 24 select study . After sign informed consent , randomize 12 intervention arm 12 placebo arm . All patient receive capsule daily consumption accord assignment , visible difference capsule . Dosage 6.5-7.5 mg/kg limit 50 mg . These capsule take period 4 month . A battery neuropsychological test administer baseline , 4 month , additional four month follow-up assess cognitive performance motor function . Emotional state assess Beck Depression Inventory three aforementioned point . After follow-up period , test result analyze compare determine efficacy safety 4-aminopyridine cognitive performance motor function patient . Mann-Whitney U use statistical analysis .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>4-Aminopyridine</mesh_term>
	<criteria>Patients ME eligible study meet follow criterion : 1 . Relapsing recurrent MEwith evolution last 6 month study begin . 2 . Both male female , age 20 65 year 3 . Neurologic EDSS 3 7 4. Who firstline immunomodulatory therapy stable disease 5 . No one outbreak per year . 6 . Absence antiepileptic antecedent electroencephalogram without epileptic activity . 7 . For female : postmenopausal surgically sterile , use acceptable method birth control 1 . History cardiovascular disease ( syncope , arrhythmia , myocardial infarction within last two year ) , systolic blood pressure great 150 less 70 mm Hg , diastolic blood pressure great 110 less 50 mm Hg , heart rate great 110 less 50 beats/minute ; impair hepatic function ( total hepatic enzyme bilirubin level great 2 time upper limit normal ) impair renal function ( creatinine level great 2 time upper limit normal ) less 6 month study 2 . Known allergy pyridinecontaining drug 3 . Neurologic , degenerative , psychiatric disorder would impair patient 's ability complete protocol 4 . Any illness abnormality would jeopardize patient safety interfere conduct study 5 . History substance abuse 6 . Inability discontinue exclude concomitant drug therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Cognitive function</keyword>
	<keyword>Multiple sclerosis</keyword>
	<keyword>4-aminopyridine</keyword>
	<keyword>Fatigue</keyword>
</DOC>